194 related articles for article (PubMed ID: 19440565)
1. Long-term response rates to infliximab therapy for Crohn's disease in an outpatient cohort.
Teshima CW; Thompson A; Dhanoa L; Dieleman LA; Fedorak RN
Can J Gastroenterol; 2009 May; 23(5):348-52. PubMed ID: 19440565
[TBL] [Abstract][Full Text] [Related]
2. Methotrexate for induction of remission in refractory Crohn's disease.
McDonald JW; Tsoulis DJ; Macdonald JK; Feagan BG
Cochrane Database Syst Rev; 2012 Dec; 12():CD003459. PubMed ID: 23235598
[TBL] [Abstract][Full Text] [Related]
3. Immunomodulators and "on demand" therapy with infliximab in Crohn's disease: clinical experience with 400 infusions.
Kinney T; Rawlins M; Kozarek R; France R; Patterson D
Am J Gastroenterol; 2003 Mar; 98(3):608-12. PubMed ID: 12650795
[TBL] [Abstract][Full Text] [Related]
4. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.
Behm BW; Bickston SJ
Cochrane Database Syst Rev; 2008 Jan; (1):CD006893. PubMed ID: 18254120
[TBL] [Abstract][Full Text] [Related]
5. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease.
Chande N; Townsend CM; Parker CE; MacDonald JK
Cochrane Database Syst Rev; 2016 Oct; 10(10):CD000545. PubMed ID: 27783843
[TBL] [Abstract][Full Text] [Related]
6. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease.
Chande N; Tsoulis DJ; MacDonald JK
Cochrane Database Syst Rev; 2013 Apr; (4):CD000545. PubMed ID: 23633304
[TBL] [Abstract][Full Text] [Related]
7. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.
Borrelli O; Bascietto C; Viola F; Bueno de Mesquita M; Barbato M; Mancini V; Bosco S; Cucchiara S
Dig Liver Dis; 2004 May; 36(5):342-7. PubMed ID: 15191204
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of infliximab in pediatric Crohn's disease: a randomized multicenter open-label trial comparing scheduled to on demand maintenance therapy.
Ruemmele FM; Lachaux A; Cézard JP; Morali A; Maurage C; Giniès JL; Viola S; Goulet O; Lamireau T; Scaillon M; Breton A; Sarles J;
Inflamm Bowel Dis; 2009 Mar; 15(3):388-94. PubMed ID: 19023899
[TBL] [Abstract][Full Text] [Related]
9. Efficacy, tolerability, and predictors of response to infliximab therapy for Crohn's disease: a large single centre experience.
Sprakes MB; Ford AC; Warren L; Greer D; Hamlin J
J Crohns Colitis; 2012 Mar; 6(2):143-53. PubMed ID: 22325168
[TBL] [Abstract][Full Text] [Related]
10. Combining infliximab with methotrexate for the induction and maintenance of remission in refractory Crohn's disease: a controlled pilot study.
Schröder O; Blumenstein I; Stein J
Eur J Gastroenterol Hepatol; 2006 Jan; 18(1):11-6. PubMed ID: 16357613
[TBL] [Abstract][Full Text] [Related]
11. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease.
Maser EA; Villela R; Silverberg MS; Greenberg GR
Clin Gastroenterol Hepatol; 2006 Oct; 4(10):1248-54. PubMed ID: 16931170
[TBL] [Abstract][Full Text] [Related]
12. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial.
Van Assche G; Magdelaine-Beuzelin C; D'Haens G; Baert F; Noman M; Vermeire S; Ternant D; Watier H; Paintaud G; Rutgeerts P
Gastroenterology; 2008 Jun; 134(7):1861-8. PubMed ID: 18440315
[TBL] [Abstract][Full Text] [Related]
13. Thiopurines and their optimization during infliximab induction and maintenance: A retrospective study in Crohn's disease.
Luber RP; Dawson L; Munari S; Kariyawasam VC; Martin C; Gibson PR; Sparrow MP; Ward MG
J Gastroenterol Hepatol; 2021 Apr; 36(4):990-998. PubMed ID: 32881046
[TBL] [Abstract][Full Text] [Related]
14. Infliximab delays but does not avoid the need for surgery in treatment-resistant pediatric Crohn' disease.
Afzal NA; Ozzard A; Keady S; Thomson M; Murch S; Heuschkel R
Dig Dis Sci; 2007 Dec; 52(12):3329-33. PubMed ID: 17805970
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of repeated infliximab infusions for Crohn's disease: 1-year clinical experience.
Cohen RD
Inflamm Bowel Dis; 2001 May; 7 Suppl 1():S17-22. PubMed ID: 11380038
[TBL] [Abstract][Full Text] [Related]
16. Managing immunogenic responses to infliximab: treatment implications for patients with Crohn's disease.
Han PD; Cohen RD
Drugs; 2004; 64(16):1767-77. PubMed ID: 15301561
[TBL] [Abstract][Full Text] [Related]
17. Open-label infliximab therapy in Crohn's disease: a long-term multicenter study of efficacy, safety and predictors of response.
González-Lama Y; López-San Román A; Marín-Jiménez I; Casis B; Vera I; Bermejo F; Pérez-Calle JL; Taxonera C; Martínez-Silva F; Menchén L; Martínez-Montiel P; Calvo M; Carneros JA; López P; Mendoza JL; Milicua JM; Huerta A; Sánchez F; Abreu L; López-Palacios N; Maté J; Gisbert JP;
Gastroenterol Hepatol; 2008; 31(7):421-6. PubMed ID: 18783686
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Infliximab Therapy and Predictors of Response in Korean Patients with Crohn's Disease: A Nationwide, Multicenter Study.
Choi CH; Song ID; Kim YH; Koo JS; Kim YS; Kim JS; Kim N; Kim ES; Kim JH; Kim JW; Kim TO; Kim HS; Kim HJ; Park YS; Park DI; Park SJ; Song HJ; Shin SJ; Yang SK; Ye BD; Lee KM; Lee BI; Lee SY; Lee CK; Im JP; Jang BI; Jeon TJ; Cho YK; Chang SK; Jeon SR; Jung SA; Jeen YT; Cha JM; Han DS; Kim WH;
Yonsei Med J; 2016 Nov; 57(6):1376-85. PubMed ID: 27593865
[TBL] [Abstract][Full Text] [Related]
19. Retrospective Evaluation of the Safety and Effect of Adalimumab Therapy (RESEAT) in pediatric Crohn's disease.
Rosh JR; Lerer T; Markowitz J; Goli SR; Mamula P; Noe JD; Pfefferkorn MD; Kelleher KT; Griffiths AM; Kugathasan S; Keljo D; Oliva-Hemker M; Crandall W; Carvalho RS; Mack DR; Hyams JS
Am J Gastroenterol; 2009 Dec; 104(12):3042-9. PubMed ID: 19724267
[TBL] [Abstract][Full Text] [Related]
20. Infliximab in treatment of Crohn's disease: the Milan experience.
Ardizzone S; Colombo E; Maconi G; Bollani S; Manzionna G; Petrone MC; Bianchi Porro G
Dig Liver Dis; 2002 Jun; 34(6):411-8. PubMed ID: 12132788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
